Brief: Madrigal Announces US Availability Of Drug For Treatment Of Fatty Liver Disease NASH
09/04/2024 14:43
April 9 (Reuters) - Madrigal Pharmaceuticals Inc
MDGL.O :
* MADRIGAL PHARMACEUTICALS ANNOUNCES U.S. AVAILABILITY OF
REZDIFFRA™ (RESMETIROM) FOR THE TREATMENT OF PATIENTS WITH
NONCIRRHOTIC NASH WITH MODERATE TO ADVANCED LIVER FIBROSIS
Source text for Eikon: ID:nGNX2QkSdk
Further company coverage: MDGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)